Posts by Sandra Ansanay-Alex
SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology
SOPHiA GENETICS is a leader in AI-driven precision medicine based in Lausanne (Switzerland). The company announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions. SOPHiA DDM™ Digital Twins uses each patient’s unique…
Read More19th Innovation Day at HUG: Meet the Winners!
At their 19th Innovation Day, the Geneva University Hospitals (HUG) highlighted 16 innovative projects from the hospital and academic sectors, grouped into three categories: Proof of Concept, Prototype, and Launch-Ready Product. Top 3 Awarded Projects: 🥇 Flow Twin: A 3D modeling platform of brain vessels for training, planning personalized endovascular procedures, and testing new…
Read MoreADC Therapeutics Announces $60 Million Private Placement
ADC Therapeutics SA, a Vaud-based commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $60.0 million private investment in public equity (“PIPE”) financing. In the PIPE, ADC Therapeutics…
Read MoreRelief Therapeutics merges with NeuroX to form MindMaze Therapeutics
The new entity, valued at CHF 1.1 billion, is positioned as a leader in neurotechnology. The transaction is expected to close in December 2025. RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, and NeuroX Group SA (NeuroX), a privately held company focused on digital…
Read MoreLICR, CHUV and UNIL extend their collaboration and renew their partnership
The Canton of Vaud, the Lausanne University Hospital (CHUV), the University of Lausanne (UNIL) and the Ludwig Institute for Cancer Research (LICR) have signed a new agreement. This agreement extends the presence of the Ludwig branch in Lausanne and strengthens their collaboration. This partnership has already attracted world-renowned scientists in the field of cancer. It…
Read MoreUCB Farchim Invests Over CHF 100 Million and Creates 80 New Jobs in Bulle
UCB Farchim, the Swiss subsidiary of Belgian biopharmaceutical group UCB, has announced a major new phase of development for its Bulle (Fribourg) site, with more than CHF 100 million in new investments and the creation of 80 additional jobs by 2030. Since opening in 1996, UCB has invested nearly CHF 700 million in its…
Read MoreHemostOD Secures CHF 4.3M Seed Extension
HemostOD, a Swiss Health Valley company pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets, announces the successful closing of a CHF 4.3 million Seed-extension financing. The round was co-led by Polytech Ventures and Orenok Holdings, with additional participation from the Lichtsteiner Foundation and other private investors. Proceeds from this financing…
Read MoreAI-Powered Precision Oncology: NAIPO Launches in Switzerland
A new national initiative, NAIPO (National AI Initiative for Precision Oncology), is set to transform cancer care in Switzerland by leveraging artificial intelligence (AI) to enable truly personalized treatments. Led by the EPFL AI Center and ETH AI Center, NAIPO will run over four years and bring together a large, interdisciplinary team from Swiss…
Read MoreUndae Science and StudentsPool Supported by FIT
Two Swiss Health Valley startups supported by Fondation pour l’Innovation Technologique (FIT) are tackling some of healthcare’s most pressing challenges: diagnosing sleep disorders and addressing critical staff shortages. Undae Science: Making Sleep Monitoring Easier and More Accurate Sleep disorders affect one in three people in Switzerland and cost the economy more than CHF 10…
Read MoreGimv announces a CHF 28 Million Investment in Spineart
The European investment company listed on Euronext Brussels is thereby becoming a major shareholder. These funds will be used to strengthen Spineart’s organisation and commercial processes, pursue its geographical expansion in certain markets such as the United States, and continue the development of innovative products. Spineart is a rapidly growing Geneva-based medical device company.…
Read More